Robert G. Kramer's Insider Trades & SAST Disclosures
Robert G. Kramer's most recent trade in Emergent Biosolutions Inc was a trade of 141,539 Employee Stock Option (Right to buy) done . Disclosure was reported to the exchange on June 9, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert G. Kramer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 141,539 | 535,051 | - | - | Employee Stock Option (Right to buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 141,539 | 506,059 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 70,769 | 364,520 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 38,462 | 293,751 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 38,462 | 258,182 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 19,231 | 255,289 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.38 per share. | 28 Feb 2023 | 3,226 | 103,298 (0%) | 0% | 12.4 | 39,938 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.71 per share. | 23 Feb 2023 | 1,591 | 106,524 (0%) | 0% | 13.7 | 21,813 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.30 per share. | 23 Feb 2023 | 1,428 | 108,115 (0%) | 0% | 14.3 | 20,420 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.25 per share. | 08 Feb 2023 | 4,944 | 109,543 (0%) | 0% | 13.3 | 65,508 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 278 | 114,487 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 135,330 | 135,330 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 55,582 | 248,684 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 33,833 | 193,102 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.64 per share. | 28 Feb 2022 | 1,715 | 246,969 (0%) | 0% | 39.6 | 67,983 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.47 per share. | 23 Feb 2022 | 2,034 | 159,269 (0%) | 0% | 42.5 | 86,384 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.23 per share. | 23 Feb 2022 | 1,419 | 161,303 (0%) | 0% | 42.2 | 59,924 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.23 per share. | 22 Feb 2022 | 4,595 | 162,722 (0%) | 0% | 42.2 | 194,047 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 4,264 | 167,317 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.62 per share. | 08 May 2021 | 94 | 163,053 (0%) | 0% | 61.6 | 5,792 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 59,898 | 59,898 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 14,975 | 168,148 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 14,975 | 153,173 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.49 per share. | 24 Feb 2021 | 2,425 | 165,723 (0%) | 0% | 93.5 | 226,713 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.15 per share. | 24 Feb 2021 | 1,716 | 164,007 (0%) | 0% | 97.1 | 166,709 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.15 per share. | 24 Feb 2021 | 860 | 163,147 (0%) | 0% | 97.2 | 83,549 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.45 per share. | 09 Feb 2021 | 3,870 | 138,298 (0%) | 0% | 123.5 | 477,752 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 2,958 | 142,168 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.45 per share. | 09 Feb 2021 | 423 | 138,198 (0%) | 0% | 123.4 | 52,219 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 323 | 138,621 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 120.03 per share. | 08 Feb 2021 | 32,397 | 139,210 (0%) | 0% | 120.0 | 3,888,612 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 32,397 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 08 Feb 2021 | 32,397 | 171,607 (0%) | 0% | 30.9 | 999,771 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 13,000 | 19,638 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 120.03 per share. | 08 Feb 2021 | 13,000 | 139,210 (0%) | 0% | 120.0 | 1,560,390 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.63 per share. | 08 Feb 2021 | 13,000 | 152,210 (0%) | 0% | 30.6 | 398,190 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 21,900 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 110.03 per share. | 20 Jan 2021 | 21,900 | 139,210 (0%) | 0% | 110.0 | 2,409,657 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.45 per share. | 20 Jan 2021 | 21,900 | 161,110 (0%) | 0% | 26.5 | 579,255 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 20 Jan 2021 | 2,232 | 139,210 (0%) | 0% | 110 | 245,520 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 2,232 | 21,900 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.45 per share. | 20 Jan 2021 | 2,232 | 141,442 (0%) | 0% | 26.4 | 59,036 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.62 per share. | 15 Jan 2021 | 19,026 | 158,236 (0%) | 0% | 25.6 | 487,446 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 106.01 per share. | 15 Jan 2021 | 19,026 | 139,210 (0%) | 0% | 106.0 | 2,016,901 | Common Stock |
| Emergent Biosolutions Inc | Robert G. Kramer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 19,026 | 0 | - | - | Employee Stock Options (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges